Nachrichten zur Arbutus Biopharma Corp. Aktie

Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates

Arbutus (ABUS) delivered earnings and revenue surprises of -44.44% and 10.25%, respectively, for the quarter ended March 2025. Do the…

Arbutus Biopharma: Focused On HBV With A Potentially Huge Litigation Wildcard

…

Arbutus Biopharma: The Markman Win Is A Good Milestone But Uncertainty Remains

…

Moderna: Lizenzgebühren an Arbutus im Fokus - Aktienanalyse

New York (www.aktiencheck.de) - Moderna-Aktienanalyse von Jefferies & Co: Michael Yee, Analyst von Jefferies & Co, rät in einer aktuellen Aktienanalyse…

Arbutus Biopharma jumps after claim construction order in patent fight with Moderna

…

Earnings call: Arbutus Biopharma outlines HBV strategy and financial health By Investing.com

Earnings call: Arbutus Biopharma outlines HBV strategy and financial health…